^
Association details:
| Biomarker: | MSI-H/dMMR + MLH1 deletion + PMS2 deletion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete Pathologic Response After Concurrent Treatment with Pembrolizumab and Radiotherapy in Metastatic Colorectal Cancer: A Case Report
Published date:
04/13/2021
Excerpt:
...64-year-old patient diagnosed with mCRC who experienced a complete pathological response (pCR) after successfully conversion treatment with pembrolizumab and RT....intestinal biopsy samples revealed loss of MLH1 and PMS2 expression....combination therapy appears to be a potential treatment for dMMR/MSI-H mCRC...
DOI:
https://doi.org/10.2147/OTT.S298333
